Pulmonary Embolism Subacute Massive

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2021-05-18
Clinical Trial Update: Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism [Phase 4]
Phase 4 trial update on standard-dose apixaban after very low-dose thrombolysis for acute intermediate-high risk acute pulmonary embolism; t…